Research & Development
Vitrolife acquires global licensing rights to technology for embryo transfer for USD5.0m
12 January 2018 -

Medical device company Vitrolife AB (STO:VITR) announced on Thursday the acquisition of exclusive global licensing rights in the IVF field regarding a technology that can be used for embryo transfer in connection with IVF treatments for an initial purchase price of USD5m.

This purchase price was paid in cash and was financed by available cash balances. In addition to this initial purchase price, additional purchase prices and royalties may be paid in relation to sales.

Reportedly, Vitrolife intends to commercialise the technology by marketing a unique embryo transfer catheter. CrossBay Medical Inc has developed and patented a balloon technology that can easily pass through difficult areas. On the basis of this technology CrossBay has developed an embryo transfer catheter which is approved by the FDA and CE-marked, with the aim of making all transfers uncomplicated and standardised. This product has not yet been launched on the market.

Vitrolife intends to launch low volumes of the product during the second half of the year in selected markets, amongst other things with a view to collecting customer data on the product's advantages at the same time as preparations take place, for example for high volume production.

According to the company, this acquisition broadens its product range and supports Vitrolife's ambition to offer IVF clinics the most effective products in its efforts to assist patients' desire to have children.

This acquisition is expected to impact EBITDA per share marginally negatively during 2018 to 2020 and positively as from 2021.

Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.